You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Kuur Therapeutics reported interim data on Thursday on its autologous GD2-targeting CAR NK-cell therapy, KUR-501, from a Phase I trial involving relapsed or refractory neuroblastoma patients.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.
This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.